Co-founder & Chief Executive Officer
François-Henri holds an MSc in Management from ESSEC Business School. Prior to founding nova, he spent 4 years with the investment bank Lehman Brothers in London and Tokyo where he has developed an expertise in financial engineering, deal structuring & execution. François-Henri has participated in securitization deals across a wide range of assets representing total completed financings in excess of US$ 500 million in Europe and Asia.
As Novadiscovery’s cofounder and CEO since 2010, François-Henri has honed a variety of skills ranging from corporate structuring to business development and people management.
Co-founder & Chief Technology Officer
Frederic graduated from Ecole Polytechnique in Paris with an Applied Mathematics Master in Probabilities and Finance.
He then worked for 12 years in financial market modelling and quantitative trading across London, Tokyo and Singapore, most recently as Managing Director for Standard Chartered Bank. During that time Frederic has managed teams of traders, quants, computer scientists and IT engineers to build large yet efficient and scalable analytics and trading frameworks.
His focus is on simulated outcome based reasoning and decision making where model hypothesis are always tested through the prism of scenarios and large scale simulations.
Chief Scientific Officer
David duVerle received his Ph.D. in Bioinformatics from the University of Kyoto in 2012, after an M.Sc. in Artificial Intelligence at Pierre & Marie Curie University in Paris.
Before joining NOVA, he was an assistant professor at the University of Tokyo’s Graduate School of Frontier Sciences with a joint position at the AI Research Center (AIRC), working on applications of Machine Learning and algorithmic techniques to novel high-dimensional problems in genomics and other emerging pluridisciplinary fields. His past projects have covered many aspects of systems biology and high-throughput omics data analysis, as well as personalised medicine and genomic privacy. His last research before joining NOVA included the modelling and analysis of Single Cell sequencing data, with a view toward better understanding early oncogenesis and tumour progression.